Physician profile
Jan Hester
NPI 1023261534
$823.77
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.64 · 2020: $79.06 · 2021: $167 · 2022: $88.17 · 2023: $68.23 · 2024: $229 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $250.79 | 2020-2025 | Mounjaro, Zepbound, Reyvow |
| Novo Nordisk INC | $102.66 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $93.92 | 2021 | |
| Exact Sciences Corporation | $82.85 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $73.33 | 2019-2024 | |
| Amgen INC. | $65.20 | 2022-2025 | Otezla, Repatha |
| Astellas Pharma US INC | $23.45 | 2024 | Veozah |
| Pfizer INC. | $21.46 | 2024 | |
| Abbott Laboratories | $19.79 | 2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $17.96 | 2019 | |
| Dermira, INC. | $17.49 | 2020 | |
| Shire North American Group INC | $15.91 | 2019 | |
| Pulmonx Corporation | $15.02 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Abbvie INC. | $12.82 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.